Next Article in Journal
Magnetic and MRI Contrast Properties of HumAfFt-SPIONs: Investigating Superparamagnetic Behavior and Enhanced T2-Weighted Imaging Performance
Next Article in Special Issue
The Role of Biomarkers in Temporomandibular Disorders: A Systematic Review
Previous Article in Journal
Current Research Trends in Glioblastoma: Focus on Receptor Tyrosine Kinases
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 26
Issue 8
10.3390/ijms26083504
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Do Single-Nucleotide Polymorphisms Affect Pain Intensity and Sufentanil Analgesia After Pediatric Scoliosis Correction Surgery?

by
Aleksander Turczynowicz
1,*,
Jakub Równy
1,
Weronika Przontka
1,
Magdalena Grzesik
2,
Piotr Jakubów
1 and
Oksana Kowalczuk
3
1
Department of Anesthesiology and Intensive Care for Children and Adolescents with Postoperative and Pain Treatment Unit, Medical University of Bialystok, 15-274 Bialystok, Poland
2
Institute of Psychology, University of Lodz, 90-128 Lodz, Poland
3
Department of Clinical Molecular Biology, Medical University of Bialystok, 15-269 Bialystok, Poland
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2025, 26(8), 3504; https://doi.org/10.3390/ijms26083504
Submission received: 12 March 2025 / Revised: 3 April 2025 / Accepted: 7 April 2025 / Published: 9 April 2025
(This article belongs to the Special Issue Pain in Human Health and Disease)
Browse Figure
Review Reports Versions Notes

Abstract

Pain management in children remains a challenge. Postoperative pain assessment, which currently relies on behavioral and subjective scales, could be enhanced by the identification of single nucleotide polymorphisms effect on pain thresholds and opioid metabolism. This study explores the impact of nine SNPs—rs1799971, rs4680, rs4633, rs6269, rs4818 (with catechol-o-methyltransferase haplotypes), rs7832704, rs1801253, and rs1045642—on postoperative pain intensity, opioid requirements, coanalgesic use, C-reactive protein levels, and post-anesthesia care unit length of stay. This study involved 42 pediatric patients undergoing scoliosis correction surgery with postoperative sufentanil infusion. The genotyping was performed using real-time PCR with peripheral blood samples. Patients with the rs1801253 ADRB1 GG genotype showed significantly lower 24 h NRS pain ratings (p = 0.032) and lower sufentanil infusion rates at the level of statistical tendency (p = 0.093). Patients with the rs1205 CRP CT genotype had a shorter PACU length of stay (p = 0.012). In contrast, those with the rs1045642 ABCB1 GG genotype had a longer PACU stay by 0.72 h (p = 0.046). No significant associations were found for OPRM1 rs1799971, COMT, or ENPP2 SNPs. ADRB1 rs1801253may be a novel SNP indicating higher postoperative pain risk, while rs1205 CRP and rs1045642 ABCB1 could predict increased care requirements in PACUs. The ADRB1 rs1801253 SNP may also predict opioid demand. These results suggest SNPs should be considered in acute pain assessment.

1. Introduction

Pain treatment in children is a challenging part of clinical practice due to difficulties in accurately assessing pain based on patients’ subjective reports. This is often affected by language skills, as well as cognitive and emotional immaturity, leading to incorrect postoperative pain intensity estimates and insufficient pain control [1,2,3].
Currently, behavioral scales such as NRS (Numerical Rating Scale), VAS (Visual Analogue Scale), Wong–Baker, and FLACC (Face, Legs, Activity, Consolability, Cry) are used to assess pain, especially in non-verbal patients. However, these scales have limitations since pain assessment is highly subjective [4,5,6].
In the case of postoperative pain, insufficient treatment may result in long-term negative outcomes from surgical procedures, such as chronic post-surgical pain. It is estimated that 11% to 13% of patients under the age of 18 experience chronic post-surgical pain [7,8,9].
Long-term studies on unoperated idiopathic scoliosis indicate the progression of disability and chronic pain. In pediatric patients, the percentage of lower back pain after surgery ranges from 7% to 77%. Even after several years, many patients still report back pain [10,11,12,13,14].
Patients undergoing scoliosis correction surgery are at high risk of developing chronic post-surgical pain. This extensive surgery causes significant tissue damage and requires postoperative pain treatment with highly potent opioids—fentanyl, remifentanil, and sufentanil [15,16].
Postoperatively, patients may not report any symptoms, but neurological exams often show impaired consciousness, raising the question of whether this is due to sufficient analgesic effect or excessive opioid sedation.
A challenge in pediatric pain therapy stems from differences in metabolism and body composition. Faster metabolic rate and a large volume of distribution due to a higher water content in children’s bodies significantly affect the pharmacokinetics and pharmacodynamics of opioids, the primary medication for intense postoperative pain [17].
In the scientific literature, research has focused on single-nucleotide polymorphisms (SNPs) and their effects on opioid metabolism, pain threshold, and pain intensity in both chronic and postoperative pain [18,19,20].
Commonly studied SNPs include those in the mu-opioid receptor gene rs1799971 A118G, in which the G allele is associated with reduced analgesic response to morphine due to altered μ-opioid receptor function. Catechol-O-methyltransferase (COMT) is an enzyme regulating epinephrine, norepinephrine, and dopamine degradation, which are involved in the modulation of pain pathways. Four SNPs—rs4680, rs4633, rs6269, and rs4818—located in the COMT gene affect enzyme thermostability and function. The ATP-binding cassette 1 gene and ABCB1 C3435T SNP have established significance for opioid metabolism, as the P-glycoprotein encoded by ABCB1 is responsible for the transmembrane transport of opioids [21,22,23].
Recent studies have also investigated other SNPs related to opioids and pain sensation, such as ADRB1 rs1801253 (beta-adrenergic receptor 1) rs1801253 causes a Gly389Arg amino acid substitution at the intracellular C-terminus of the β1-adrenergic receptor. It has been linked to variability in pain perception and analgesic effects of opioids such as fentanyl and remifentanil in Asian populations [24,25,26].
ENPP2 encoding autotaxin, or ectonucleotide pyrophosphatase/phosphodiesterase family member 2, plays a role in nociceptive pain through inflammation, along with the C-reactive protein (CRP) SNP, which might affect postoperative pain through nociceptive pathways [27,28,29].
Most of these studies concern adults; however, significantly fewer studies focus on children [16,30,31,32]. Therefore, this article explores the impact of nine different SNPs (rs1799971, rs4680, rs4633, rs6269, rs4818, (as well as COMT haplotypes), rs7832704, rs1801253, rs1045642, and rs1205) on postoperative pain intensity, opioid doses, patient pain ratings, inflammation (measured by C-reactive protein levels), PACU (post-anesthesia care unit) length of stay, and coanalgesic use in pediatric patients (0–18 years old) undergoing elective scoliosis correction surgery. The goal is to determine if these SNPs could contribute to personalized therapy for acute and inflammatory pain in children, potentially improving recovery and reducing the risk of chronic pain or opioid dependence [33,34,35].

2. Results

2.1. Descriptive Statistics of Analyzed Clinical Parameters and Demographic Data

Forty-seven patients were enrolled in the study after obtaining signed informed consent. Due to the sampling error (n = 3) and missing samples due to laboratory error (n = 2), the final group included in the analysis comprised 42 patients. In the analyzed sample of N = 42 patients, there was a significant overrepresentation of females, accounting for 76.2% (n = 32) of the cohort, while males constituted a mere 23.8% (n = 10). The mean age of the participants was 13.33 years, with a standard deviation of 3.67 years, spanning from 5 to 18 years, suggesting a relatively narrow age distribution around adolescence. The mean weight of the patients was 47.72 kg, with standard deviation of 16.39, ranging from 16.5 kg to 82 kg. All demographic data are presented in Table 1, and descriptive statistics of the analyzed clinical parameters are shown in Table 2.

2.2. Influence of Confounders on Clinical Parameters

A regression-based approach was used to verify the influence of polymorphisms on clinical parameters. Linear regression models were applied to verify the influence of polymorphisms on numeric clinical parameters, while logistic regression was used to verify the association between polymorphisms and the usage of coanalgesics, as the usage of coanalgesics was described with a binary variable. Multivariate models were built to consider important confounders; however, given the total number of patients, each model included one polymorphism and one confounder as independent variables and a clinical parameter as the dependent variable. The considered confounders were age, gender, and type of procedure. Preliminarily, for each clinical parameter, its most important confounder was identified based on the lowest p value in the univariate models, and taking into account the condition of p < 0.157 (linear regressions) or p < 0.250 (logistic regressions) [36,37]. The outcomes of the univariate modelling between the confounders and clinical parameters are presented in Table 3. Age was selected as the most important confounder for CRP 72 h post-surgery. CRP 72 h post-surgery was higher by 6.75 in cases of patients older by one year (β = 6.75 CI95 [1.30;12.20]; p = 0.017). Gender was selected as the most important confounder for mean 24 h NRS pain rating; based on the lowest p value of 0.101, the outcome was not statistically significant, yet it suggested that females gave higher pain ratings. Age was selected as the most important confounder for sufentanil mean infusion flow rate (weight-adjusted). Procedure type was the most important confounder for PACU length of stay. PACU length of stay was shorter by 0.75 in cases of procedures other than Nuvasive or Expedium compared to Nuvasive (β = −0.75 CI95 [−1.34;−0.17]; p = 0.013). No confounder for coanalgesics fulfilled the condition of p < 0.250, and thus the impact of polymorphisms on the usage of coanalgesics was analyzed through univariate regression.

2.3. Influence of Polymorphisms on CRP 72 h Post-Surgery

A significant relationship was confirmed between rs4680 and CRP 72 h post-surgery. Patients with rs4680 AG had a higher CRP 72 h post-surgery level by 46.24 compared to patients with rs4680 AA (β = 46.24 CI95 [4.03;88.45]; p = 0.033). For graphic representation see Figure 1.
Additionally, relationships at the level of statistical tendency (p < 0.1) were found between COMT haplotype and CRP 72 h post-surgery. Patients with both ATCA/ATCA and COMT haplotypes other than ACCA/GTGG and ATCA/ATCA had lower CRP 72 h post-surgery levels compared to patients with ACCA/GTGG (β = −48.74 CI95 [−101.52;4.03], p = 0.069; β = −38.30 CI95 [−83.97;7.37], p = 0.098, respectively).

2.4. Influence of Polymorphisms on Mean 24 h NRS Pain Rating

A significant relationship was confirmed between rs1801253 ADRB1 and mean 24 h NRS pain rating. Patients with rs1801253 ADRB1 GG had a lower mean 24 h NRS pain rating by 1.92 compared to patients with rs1801253 ADRB1 CC (β = −1.92 CI95 [−3.66;−0.17]; p = 0.032). For graphic representation see Figure 1.
Additionally, a relationship at the level of statistical tendency (p < 0.1) was found between rs4818 and mean 24 h NRS pain rating. Patients with rs4818 CG had a lower mean 24 h NRS pain rating compared to patients with rs4818 CC (β = −0.64 CI95 [−1.40;0.11]; p = 0.091).

2.5. Influence of Polymorphisms on Sufentanil Mean Infusion Flow Rate (Weight-Adjusted)

No relationships with statistical significance were confirmed.
A relationship at the level of statistical tendency (p < 0.1) was found between rs1801253 ADRB1 and sufentanil mean infusion flow rate (weight-adjusted). Patients with rs1801253 ADRB1 GG had lower sufentanil mean infusion rate (weight-adjusted) compared to patients with rs1801253 ADRB1 CC (β = −0.04 CI95 [−0.08;0.01]; p = 0.093).

2.6. Influence of Polymorphisms on PACU Length of Stay

A significant relationship was confirmed between rs1205 CRP and PACU length of stay, as well as between rs1045642 ABCB1 and PACU length of stay. Patients with rs1205 CRP CT had a shorter PACU length of stay by 0.62 compared to patients with rs1205 CRP CC (β = −0.62 CI95 [−1.10;−0.14]; p = 0.012). Patients with rs1045642 ABCB1 GG had a longer PACU length of stay by 0.72 compared to patients with rs1045642 ABCB1 AA (β = 0.72 CI95 [0.01;1.43]; p = 0.046). For graphic representation see Figure 1.
Additionally, a relationship at the level of statistical tendency (p < 0.1) was found between rs1045642 ABCB1 and PACU length of stay. Patients with rs1045642 ABCB1 AG had a longer PACU length of stay compared to patients with rs1045642 ABCB1 AA (β = 0.51 CI95 [−0.08;1.09]; p = 0.087).

2.7. Influence of Polymorphisms on Usage of COANALGESICS

No relationships with statistical significance were confirmed.
Relationships at the level of statistical tendency (p < 0.1) were found between rs4818 and usage of coanalgesics, as well as between COMT haplotype and usage of coanalgesics. The odds of coanalgesic usage decreased by 70% in cases of patients with rs4818 CG compared to patients with rs4818 CC (OR = 0.30 CI95 [0.08;1.03]; p = 0.063). The odds of coanalgesic usage increased 3× in cases of patients with COMT haplotypes other than ACCA/GTGG and ATCA/ATCA, compared to patients with ACCA/GTGG (OR = 3.47 CI95 [0.82;16.32]; p = 0.099). See Table 4.

3. Discussion

Pain control after surgery in pediatric patients is still a major concern for healthcare providers [38]. Patients undergoing extensive surgeries like scoliosis correction are at risk of chronic postsurgical pain if acute pain is not properly treated. This can affect the surgery’s success and lower quality of life [35]. Pain assessment currently relies on behavioral scales, considering child developmental abilities, age, and gender. For instance, one of most important confounders for sufentanil dosage is female gender (at the level of statistical tendency) [39,40].
In this article, we explore the role of single-nucleotide polymorphisms (SNPs) in the complex interactions influencing pain perception and opioid use in the perioperative period [32,41]. The literature shows mixed results regarding SNPs’ ability to explain variation in pain perception and opioid requirements based on specific allele occurrences in different ethnic groups, e.g., Asian, European, or African [15,42,43,44].
To assess factors influencing clinical outcomes, we identified key confounders. Age, for example, influenced CRP levels post-surgery, likely due to the need for larger surgical incisions and increased spinal ossification in older patients [10]. Female gender confounded mean 24 h pain ratings without reaching statistical significance. However, this suggests that women report higher pain ratings after scoliosis correction. While female gender showed a tendency to influence 24 h pain ratings, it did not reach statistical significance. However, studies indicate that females generally experience higher postoperative pain and require more opioids [45,46,47]. Age was identified as the main factor influencing sufentanil dosage. Younger patients have a higher metabolic rate and larger distribution volumes, making weight-based opioid dosing alone insufficient [48].
We found a significant impact of rs4680 COMT on CRP levels after surgery, with higher levels in patients with the AG genotype. COMT is involved in inflammatory processes, and the A allele in the rs4680 SNP causes a non-synonymous substitution of valine to methionine at codon 158 (Val158Met), leading to changes in thermostability and variability in COMT enzymatic activity. The statistical tendency of haplotype influence on CRP levels also supports this explanation. This is a novel finding; however, it needs to be treated with caution as the study population is limited [49].
Our study also suggests that the ADRB1 rs1801253 SNP influences pain ratings within 24 h of surgery in European patients. This finding is novel, as previous research has linked this SNP to remifentanil and fentanyl analgesic effects and pain intensity primarily in Asian populations. The most interesting finding is the fact that one study on 324 patients did not find any associations between this SNP and pain sensitivity and opioid requirements. Another study on 137 Chinese women revealed the ADRB1 rs1801253 CC genotype to be associated with higher sensitivity to remifentanil analgesia [24,26]. The statistical tendency of lower pain intensity in patients carrying the CG genotype in the rs4818 SNP can be explained in the same way as for CRP levels, with the CG genotype potentially serving as a protective factor against postoperative pain [49,50,51]. Among European populations, G allele frequency is around 28%, and in Asian populations it is around 35% according to the ALPHA allele aggregator. This suggests that the results of studies regarding ADRB1 are comparable among different ethnic populations, in contrast to OPRM1 rs1799971, where the G allele in European populations is rare, thus giving no statistical effect on the investigated clinical parameters [52].
No statistically significant relationships between the SNPs and sufentanil dosage were found. However, there was a tendency for patients with the GG genotype of ADRB1 rs1801253 to require less sufentanil post-surgery than patients with the CC genotype, which aligns with lower pain intensity. This is an interesting finding considering the fact that studies on Asian populations showed that the CC genotype required lower opioid doses for effective postoperative analgesia [24,26].
PACU length of stay was significantly affected by rs1205 CRP and ABCB1 rs1045642. The shorter stay of the CT group of the rs1205 SNP might be predictive of lower pain due to a subsequent lower inflammatory response, and, furthermore, a reduced need for observation and therapeutic interventions regarding pain in the PACU. In contrast, the GG genotype of ABCB1 may act as a predictor of higher needs in patients hospitalized in the PACU with regard to the need for effective postoperative pain control before discharge [29,53].
No significant influence of the SNPs was found on the use of coanalgesics like ketamine or lidocaine. Nevertheless, the rs4818 CG group showed a statistical tendency with 70% decreased odds of needing coanalgesics (p = 0.063), approaching the significance level of p < 0.05. This supports the literature suggesting that COMT variability impacts pain perception and that rs4818 CG might predict lower pain thresholds among patients undergoing major surgery [15,16].
No significant relationships were found with the OPRM1 rs1799971 SNP, the most widely studied in pain and opioid research. This may be because the G allele, linked to higher pain and opioid needs, was rare in our group (7 out of 42, as expected for the European population), with only heterozygotes and no GG homozygotes [44].
As a result, the statistical analysis showed no influence on any clinical parameters of interest. Nonetheless, this SNP has the most substantial body of evidence, not only for its involvement in opioid metabolism, but also for its association with psychiatric disorders, such as alcohol and opioid addiction [54,55,56]. This is consistent with our previous findings on a smaller group of patients, as well as on larger cohorts of 126 and 207 European subjects, that this SNP may not predict pain thresholds or opioid needs in European populations [32,43,50].

4. Materials and Methods

4.1. Patient Population

This study was conducted at a clinical hospital, where children referred from lower reference centers nationwide were directed. Patients were admitted based on a referral order to the Orthopedics Department.
The cohort study ran from May 2022 to October 2024, involving patients scheduled for scoliosis correction surgery. The study followed the Declaration of Helsinki and received approval from the Bioethics Committee of the Medical University of Bialystok (consent no. APK.002.512.2021, 16 December 2021).
Inclusion criteria: children aged 0–18 years scheduled for scoliosis surgery, initial pediatric evaluation, and ASA (American Society of Anesthesiologists) I–II classification (assessed by an anesthesiologist with a legal guardian present). Eligible patients had no significant health issues besides scoliosis, or had stable, controlled symptoms.
Exclusion criteria: untreated or poorly controlled neurological disorders; neuropathic pain requiring opioids within three months prior to surgery; pulmonary conditions identified through spirometry, particularly restrictive lung diseases; metabolic disorders; cardiological issues (including arrhythmias and untreated congenital heart defects); and psychiatric disorders (such as borderline, histrionic, and schizoid personality disorders, phobias, anxiety disorders, depressive disorders, atypical bipolar disorders, and suspected addictions).
Symptoms of psychiatric disorders were evaluated during routine pediatric and anesthetic evaluations, and further psychological consultations were provided if needed. Patients who did not meet the criteria were qualified to have alternative treatment options.

4.2. Anesthesia and Analgesia

Before surgery, patients received oral midazolam (0.2 mg/kg) as a premedication, along with a crystalloid infusion after establishing peripheral intravenous access.
Upon arrival in the operating theater, patient identity and medical records were verified. Vital signs, including ECG, etCO2, saturation, and oxygen measurements, were continuously monitored.
Each patient received two peripheral venous catheters and a radial artery cannula for invasive blood pressure monitoring. Anesthesia depth was monitored using the BiSpectral Index (BIS), and peripheral nerve potential measurements were used to evaluate nerve damage [11].
Anesthesia induction included propofol and rocuronium, with dosages based on body weight, followed by remifentanil infusion and intubation using a reinforced tube. Anesthesia was maintained using TIVA-TCI (Total Intravenous Anesthesia—Target Controlled Infusion) with propofol and remifentanil (without additional neuromuscular blockers), adjusting infusion rates based on BIS to maintain a range of 35–50 [57].

4.3. Postoperative Pain Treatment

Before the end of the surgery and transfer to the postoperative ward, a 0.1 μg/kg/h sufentanil infusion was started to maintain analgesia after the remifentanil infusion. After operation, all patients received 15 mg/kg paracetamol and 16 mg/kg metamizole. Pain was assessed using the NRS.
The sufentanil infusion rate at admission, as well as pain score after extubation, at discharge from the postoperative ward, and 24 h after surgery were recorded. From this, the weight-adjusted mean sufentanil infusion rate and mean 24 h NRS pain intensity were calculated for statistical analysis [4,6]. CRP levels were measured 72 h after surgery as an indicator of inflammatory pain. If severe pain or adverse effects (e.g., disorientation, excessive sedation, breathing problems) occurred, coanalgesics like lidocaine (1–1.5 mg/kg/h) or ketamine (0.2–0.3 mg/kg) were added to maintain effective sufentanil doses.

4.4. Genotyping Data and Laboratory Analysis

To perform laboratory analysis, genetic blood samples (1.2 mL EDTA tubes) were collected before surgery and blood transfusions. Every sample had to be cured by mixing with erythrocyte-lysing solution, cooled down to 4 °C, and centrifuged for 10 min at 2500 rpm in a standard laboratory centrifuge.
Genotyping was performed using Roche Diagnostics LightCycler® 480 (Roche Diagnostics International Ltd., Rotkreuz, Switzerland) real-time PCR hybridization probes for two-sequence SNPs with ready-made assays (TaqMan™ SNP Genotyping Assay: rs1799971, rs9397685, rs1205, rs6269, rs7832704, and rs1801253; TaqMan™ Drug Metabolism Assay: rs4680, rs4818, rs4633, and rs1045642 from Applied-Biosystems™ (Foster City, CA, USA)) and TaqMan Genotyping Master Mix. All genotyping and post-genotyping analyses followed the manufacturers’ protocols.

4.5. Statistical Analysis

Statistical analysis was performed in R software (version R4.4.2). Clinical parameters were described with mean and standard deviation (SD) in cases of numeric parameters with normal distributions, median and interquartile range (IQR) in cases of numeric parameters with non-normal distributions, and with n (%) in cases of categorical parameters. Distribution normality was verified with the Shapiro–Wilk test, skewness, and kurtosis. The influence of polymorphisms on clinical parameters was assessed with regression methods to consider confounders. In cases of clinical parameters of numeric type, linear regression was used; in cases of clinical parameters of categorical type, logistic regression was employed. Regression models verified how each polymorphism impacted each clinical parameter. Models were built as follows: the dependent variable was clinical parameter; independent variables were polymorphism and best confounder (one confounder was included in each model due to n = 42 number of patients). Potential confounders were age, sex, and type of procedure. For each clinical parameter, the best confounder was selected based on the lowest p value from the univariate models between the clinical parameter and the confounders, assuming that the minimum cut-off for p value in linear regression was p < 0.157 and the minimum cut-off for p value in logistic regression was p < 0.250. All statistical tests assumed significance when p < 0.05. Associations with p < 0.1 were indicated as a statistical tendency.

5. Limitations of the Study

This study has some limitations. The sample size (n = 42) restricted the complexity of statistical models, limiting us to two-predictor models. Additionally, low counts in some analyses reduced statistical power, requiring cautious interpretation of the results. While this approach provided meaningful insights, larger studies are needed to explore more complex interactions.
Additionally, although the p-values received from the two-predictor regression models indicated significant associations, multiple-testing correction led to adjusted p-values that did not reach significance (See Table S1). This suggests that while the observed effects are promising, replication in larger samples is needed to confirm their robustness.
One of the criteria of eligibility for the study was no previous psychiatric disorders, including anxiety disorders and personality disorders. A lack of control for postoperative anxiety, nonetheless, is a limitation of this study. This factor could also contribute to variability in the results. Another limitation is the potential for selection bias due to the non-randomized nature of the sample.
Ethnic variability in SNPs is a limitation not only of this study, but also of the use of polymorphisms as a universal tool for improving pain assessment, as allele frequencies differ across ethnic groups. Consequently, a given SNP may serve as a significant pain biomarker only within a specific ethnic population.
Despite these constraints, our findings on both levels of statistical significance and statistical tendencies (p < 0,1) provide valuable insights and highlight the need for further research with larger cohorts to validate and expand upon these results.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms26083504/s1.

Author Contributions

Conceptualization, A.T. and P.J.; methodology A.T. and P.J.; validation A.T. and P.J.; formal analysis A.T., J.R. and O.K.; investigation, A.T., J.R., W.P. and O.K.; resources, P.J. and A.T.; data curation, J.R., W.P. and M.G.; writing—original draft preparation, A.T.; writing—review and editing, A.T., P.J. and M.G.; visualization, A.T.; supervision, P.J.; project administration A.T.; funding acquisition, A.T. All authors have read and agreed to the published version of the manuscript.

Funding

This research and the APC was funded by the Medical University of Bialystok, grant number B.SUB.24.148.

Institutional Review Board Statement

The study was conducted following the Declaration of Helsinki and with the consent of the Bioethics Committee of the Medical University of Bialystok (consent no. APK.002.512.2021 on 16 December 2021).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study are available on request from the corresponding author due to patient privacy reasons.

Conflicts of Interest

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Taylor, E.M.; Boyer, K.; Campbell, F.A. Pain in Hospitalized Children: A Prospective Cross-Sectional Survey of Pain Prevalence, Intensity, Assessment and Management in a Canadian Pediatric Teaching Hospital. Pain Res. Manag. 2008, 13, 25–32. [Google Scholar] [CrossRef] [PubMed]
  2. Astuto, M.; Rosano, G.; Rizzo, G.; Disma, N.; Di Cataldo, A. Methodologies for the Treatment of Acute and Chronic Nononcologic Pain in Children. Minerva Anestesiol. 2007, 73, 459–465. [Google Scholar] [PubMed]
  3. Bąbel, P. The Effect of Positive Affect on the Memory of Pain. Pain Manag. Nurs. 2017, 18, 129–136. [Google Scholar] [CrossRef]
  4. Morton, N.S. Management of Postoperative Pain in Children. Arch. Dis. Child. Educ. Pract. 2007, 92, ep14–ep19. [Google Scholar] [CrossRef]
  5. Bąbel, P.; Pieniążek, L.; Zarotyński, D. The Effect of the Type of Pain on the Accuracy of Memory of Pain and Affect. Eur. J. Pain 2015, 19, 358–368. [Google Scholar] [CrossRef]
  6. Shamim, F.; Ullah, H.; Khan, F. Postoperative Pain Assessment Using Four Behavioral Scales in Pakistani Children Undergoing Elective Surgery. Saudi J. Anaesth. 2015, 9, 174. [Google Scholar] [CrossRef]
  7. Gan, T.J. Poorly Controlled Postoperative Pain: Prevalence, Consequences, and Prevention. J. Pain Res. 2017, 10, 2287–2298. [Google Scholar] [CrossRef]
  8. Rabbitts, J.A.; Fisher, E.; Rosenbloom, B.N.; Palermo, T.M. Prevalence and Predictors of Chronic Postsurgical Pain in Children: A Systematic Review and Meta-Analysis. J. Pain 2017, 18, 605–614. [Google Scholar] [CrossRef]
  9. Fortier, M.A.; Chou, J.; Maurer, E.L.; Kain, Z.N. Acute to Chronic Postoperative Pain in Children: Preliminary Findings. J. Pediatr. Surg. 2011, 46, 1700–1705. [Google Scholar] [CrossRef]
  10. Grabala, P.; Kowalski, P.; Grabala, M. The Influence of Increased Pedicle Screw Diameter and Thicker Rods on Surgical Results in Adolescents Undergoing Posterior Spinal Fusion for Idiopathic Scoliosis. J. Clin. Med. 2024, 13, 2174. [Google Scholar] [CrossRef]
  11. Grabala, P.; Grabala, M.; Kossakowski, D.; Larysz, D. Three-Dimensional Correction for Idiopathic Scoliosis with Posterior Spinal Fusion and the Risk of Neurological Complications. Pol. Ann. Med. 2016, 23, 97–101. [Google Scholar] [CrossRef]
  12. Erwin, J.; Carlson, B.B.; Bunch, J.; Jackson, R.S.; Burton, D. Impact of Unoperated Adolescent Idiopathic Scoliosis in Adulthood: A 10-Year Analysis. Spine Deform. 2020, 8, 1009–1016. [Google Scholar] [CrossRef] [PubMed]
  13. Bas, T.; Franco, N.; Bas, P.; Bas, J.L. Pain and Disability Following Fusion for Idiopathic Adolescent Scoliosis: Prevalence and Associated Factors. Evid. Based Spine Care J. 2012, 3, 17–24. [Google Scholar] [CrossRef] [PubMed]
  14. Bagó, J.; Matamalas, A.; Pizones, J.; Betegón, J.; Sánchez-Raya, J.; Pellisé, F. Back Pain in Adolescents and Young Adults with Idiopathic Scoliosis—Identifying Factors Associated with Significant Pain—A Multivariate Logistic Regression Analysis. J. Clin. Med. 2024, 13, 2366. [Google Scholar] [CrossRef]
  15. Khalil, H.; Sereika, S.M.; Dai, F.; Alexander, S.; Conley, Y.; Gruen, G.; Meng, L.; Siska, P.; Tarkin, I.; Henker, R. OPRM1 and COMT Gene–Gene Interaction Is Associated With Postoperative Pain and Opioid Consumption After Orthopedic Trauma. Biol. Res. Nurs. 2017, 19, 170–179. [Google Scholar] [CrossRef]
  16. Wang, H.; An, J.; Zhong, S.; Qiao, S.; Zhang, L.; Zhao, L.; Wang, C. The Influence of COMT and ABCB1 Gene Polymorphisms on Sufentanil Analgesic Effect for Postoperative Pain in Children with Fracture. Medicine 2024, 103, e37980. [Google Scholar] [CrossRef]
  17. Vecchione, T.M.; Agarwal, R.; Monitto, C.L. Error Traps in Acute Pain Management in Children. Paediatr. Anaesth. 2022, 32, 982–992. [Google Scholar] [CrossRef]
  18. Choi, S.-W.; Lam, D.M.H.; Wong, S.S.C.; Shiu, H.H.C.; Wang, A.X.M.; Cheung, C.-W. Effects of Single Nucleotide Polymorphisms on Surgical and Postsurgical Opioid Requirements: A Systematic Review and Meta-Analysis. Clin. J. Pain 2017, 33, 1117–1130. [Google Scholar] [CrossRef]
  19. Ferreira Do Couto, M.L.; Fonseca, S.; Pozza, D.H. Pharmacogenetic Approaches in Personalized Medicine for Postoperative Pain Management. Biomedicines 2024, 12, 729. [Google Scholar] [CrossRef]
  20. Turczynowicz, A.; Niedźwiecka, K.; Panasiuk, D.; Pużyńska, W.; Luchowski, K.; Kondracka, J.; Jakubów, P. Single Nucleotide Polymorphisms as Predictors of Treatment Efficacy and Adverse Effects of Morphine in Palliative Medicine—A Literature Review. Palliat. Med. Pract. 2022, 17, 29–38. [Google Scholar] [CrossRef]
  21. Hwang, I.C.; Park, J.-Y.; Myung, S.-K.; Ahn, H.Y.; Fukuda, K.; Liao, Q. OPRM1 A118G Gene Variant and Postoperative Opioid Requirement. Anesthesiology 2014, 121, 825–834. [Google Scholar] [CrossRef] [PubMed]
  22. Chu, H. The Relevance of the OPRM1 118A>G GeneticVariant for Opioid Requirement in Pain Treatment: A Meta-Analysis. Pain Phys. 2019, 4, 331–340. [Google Scholar] [CrossRef]
  23. Bartošová, O.; Polanecký, O.; Perlík, F.; Adámek, S.; Slanař, O. OPRM1 and ABCB1 Polymorphisms and Their Effect on Postoperative Pain Relief With Piritramide. Physiol. Res. 2015, 64, S521–S527. [Google Scholar] [CrossRef] [PubMed]
  24. Niu, H.; Zhao, S.; Wang, Y.; Huang, S.; Zhou, R.; Wu, Z.; Song, W.; Chen, X. Influence of Genetic Variants on Remifentanil Sensitivity in Chinese Women. J. Clin. Pharm. Ther. 2022, 47, 1858–1866. [Google Scholar] [CrossRef]
  25. Moriyama, A.; Nishizawa, D.; Kasai, S.; Hasegawa, J.; Fukuda, K.; Nagashima, M.; Katoh, R.; Ikeda, K. Association Between Genetic Polymorphisms of the β1-Adrenergic Receptor and Sensitivity to Pain and Fentanyl in Patients Undergoing Painful Cosmetic Surgery. J. Pharmacol. Sci. 2013, 121, 48–57. [Google Scholar] [CrossRef]
  26. Feng, S.; Li, N.; Xu, S.; Wang, H.; Yu, W.; Lu, Y.; Cao, J.; Meng, Y. Association of ADRB1 Gene Polymorphisms with Pain Sensitivity in a Chinese Population. Int. J. Clin. Exp. Med. 2015, 8, 11514–11518. [Google Scholar]
  27. Tsuchida, R.; Nishizawa, D.; Fukuda, K.; Ichinohe, T.; Kano, K.; Kurano, M.; Ikeda, K.; Sumitani, M. Genetic Polymorphisms of ENPP2 Are Possibly Associated with Pain Severity and Opioid Dose Requirements in Patients with Inflammatory Pain Conditions: Clinical Observation Study. Int. J. Mol. Sci. 2023, 24, 6986. [Google Scholar] [CrossRef]
  28. Perry, T.E.; Muehlschlegel, J.D.; Liu, K.-Y.; Fox, A.A.; Collard, C.D.; Body, S.C.; Shernan, S.K.; CABG Genomics Investigators. C-Reactive Protein Gene Variants Are Associated with Postoperative C-Reactive Protein Levels after Coronary Artery Bypass Surgery. BMC Med. Genet. 2009, 10, 38. [Google Scholar] [CrossRef]
  29. Carlson, C.S.; Aldred, S.F.; Lee, P.K.; Tracy, R.P.; Schwartz, S.M.; Rieder, M.; Liu, K.; Williams, O.D.; Iribarren, C.; Lewis, E.C.; et al. Polymorphisms within the C-Reactive Protein (CRP) Promoter Region Are Associated with Plasma CRP Levels. Am. J. Hum. Genet. 2005, 77, 64–77. [Google Scholar] [CrossRef]
  30. Lilic, J.; Marjanovic, V.; Budic, I.; Stefanovic, N.; Stokanovic, D.; Marjanovic, G.; Jevtovic-Stoimenov, T.; Golubovic, M.; Zecevic, M.; Velickovic-Radovanovic, R. The Impact of Opioid Receptor Gene Polymorphism on Fentanyl and Alfentanil’s Analgesic Effects in the Pediatric Perioperative Period. Pharmgenomics Pers. Med. 2024, 17, 41–49. [Google Scholar] [CrossRef]
  31. Aruldhas, B.W.; Quinney, S.K.; Packiasabapathy, S.; Overholser, B.R.; Raymond, O.; Sivam, S.; Sivam, I.; Velu, S.; Montelibano, A.; Sadhasivam, S. Effects of Oxycodone Pharmacogenetics on Postoperative Analgesia and Related Clinical Outcomes in Children: A Pilot Prospective Study. Pharmacogenomics 2023, 24, 187–197. [Google Scholar] [CrossRef] [PubMed]
  32. Turczynowicz, A.; Jakubów, P.; Niedźwiecka, K.; Kondracka, J.; Pużyńska, W.; Tałałaj, M.; Guszczyn, T.; Grabala, P.; Kowalczuk, O.; Kocańda, S. Mu-Opioid Receptor 1 and C-Reactive Protein Single Nucleotide Polymorphisms as Biomarkers of Pain Intensity and Opioid Consumption. Brain Sci. 2023, 13, 1629. [Google Scholar] [CrossRef] [PubMed]
  33. Zaed, I.; Bossi, B.; Ganau, M.; Tinterri, B.; Giordano, M.; Chibbaro, S. Current State of Benefits of Enhanced Recovery After Surgery (ERAS) in Spinal Surgeries: A Systematic Review of the Literature. Neurochirurgie 2022, 68, 61–68. [Google Scholar] [CrossRef] [PubMed]
  34. Zacha, S.; Szwed, A.; Miegoń, J.; Skonieczna-Żydecka, K.; Andrzejewska, A.; Modrzejewska, E.; Horecki, M.; Jarosz, K.; Biernawska, J. Novel Interdisciplinary Enhanced Recovery after Surgery Protocol Implementation in Paediatric Orthopaedics. J. Pers. Med. 2023, 13, 1417. [Google Scholar] [CrossRef]
  35. Grabala, P.; Gregorczyk, J.; Fani, N.; Galgano, M.A.; Grabala, M. Surgical Treatment Strategies for Severe and Neglected Spinal Deformities in Children and Adolescents without the Use of Radical Three-Column Osteotomies. J. Clin. Med. 2024, 13, 4824. [Google Scholar] [CrossRef]
  36. Heinze, G.; Dunkler, D. Five Myths about Variable Selection. Transpl. Int. 2017, 30, 6–10. [Google Scholar] [CrossRef]
  37. Hosmer, D.W.; Lemeshow, S. Applied Logistic Regression, 1st ed.; Wiley: Hoboken, NJ, USA, 2000; ISBN 978-0-471-35632-5. [Google Scholar]
  38. Makhlouf, M.M.; Garibay, E.R.; Jenkins, B.N.; Kain, Z.N.; Fortier, M.A. Postoperative Pain: Factors and Tools to Improve Pain Management in Children. Pain Manag. 2019, 9, 389–397. [Google Scholar] [CrossRef]
  39. Zieliński, J.; Morawska-Kochman, M.; Zatoński, T. Pain Assessment and Management in Children in the Postoperative Period: A Review of the Most Commonly Used Postoperative Pain Assessment Tools, New Diagnostic Methods and the Latest Guidelines for Postoperative Pain Therapy in Children. Adv. Clin. Exp. Med. 2020, 29, 365–374. [Google Scholar] [CrossRef]
  40. Boric, K.; Dosenovic, S.; Jelicic Kadic, A.; Batinic, M.; Cavar, M.; Urlic, M.; Markovina, N.; Puljak, L. Interventions for Postoperative Pain in Children: An Overview of Systematic Reviews. Pediatr. Anesth. 2017, 27, 893–904. [Google Scholar] [CrossRef]
  41. Widjaja, S.S.; Ichwan, M.; Chowbay, B.; Rusdiana; Mardani, T.H.; Jayalie, V.F. Gene Polymorphism Impact on Opioid Analgesic Usage. J. Adv. Pharm. Technol. Res. 2024, 15, 135–138. [Google Scholar] [CrossRef]
  42. Sia, A.T.; Landau, R. A118G Single Nucleotide Polymorphism of Human Mu-Opioid Receptor Gene Influences Pain Perception and Patient-Controlled Intravenous Morphine Consumption after Intrathecal Morphine for Postcesarean Analgesia. Anesthesiology 2008, 109, 520–526. [Google Scholar] [CrossRef] [PubMed]
  43. Jurewicz, A.; Bohatyrewicz, A.; Pawlak, M.; Tarnowski, M.; Kurzawski, M.; Machoy-Mokrzyńska, A.; Kaczmarczyk, M.; Lubkowska, A.; Chudecka, M.; Maciejewska-Skrendo, A.; et al. No Association between Genetic Variants of the COMT and OPRM1 Genes and Pain Perception among Patients Undergoing Total Hip or Knee Arthroplasty for Primary Osteoarthritis. Genes 2022, 13, 1775. [Google Scholar] [CrossRef] [PubMed]
  44. Martin, F.J.; Amode, M.R.; Aneja, A.; Austine-Orimoloye, O.; Azov, A.G.; Barnes, I.; Becker, A.; Bennett, R.; Berry, A.; Bhai, J.; et al. Ensembl 2023. Nucleic Acids Res. 2023, 51, D933–D941. [Google Scholar] [CrossRef]
  45. Zheng, H.; Schnabel, A.; Yahiaoui-Doktor, M.; Meissner, W.; Van Aken, H.; Zahn, P.; Pogatzki-Zahn, E. Age and Preoperative Pain Are Major Confounders for Sex Differences in Postoperative Pain Outcome: A Prospective Database Analysis. PLoS ONE 2017, 12, e0178659. [Google Scholar] [CrossRef]
  46. Aubrun, F.; Salvi, N.; Coriat, P.; Riou, B. Sex- and Age-Related Differences in Morphine Requirements for Postoperative Pain Relief. Anesthesiology 2005, 103, 156–160. [Google Scholar] [CrossRef]
  47. Cepeda, M.S.; Carr, D.B. Women Experience More Pain and Require More Morphine Than Men to Achieve a Similar Degree of Analgesia. Anesth. Analg. 2003, 97, 1464–1468. [Google Scholar] [CrossRef]
  48. Ziesenitz, V.C.; Vaughns, J.D.; Koch, G.; Mikus, G.; van den Anker, J.N. Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. Clin. Pharmacokinet. 2018, 57, 125–149. [Google Scholar] [CrossRef]
  49. Smith, S.B.; Reenilä, I.; Männistö, P.T.; Slade, G.D.; Maixner, W.; Diatchenko, L.; Nackley, A.G. Epistasis between Polymorphisms in COMT, ESR1, and GCH1 Influences COMT Enzyme Activity and Pain. Pain 2014, 155, 2390–2399. [Google Scholar] [CrossRef]
  50. Matic, M.; de Hoogd, S.; de Wildt, S.N.; Tibboel, D.; Knibbe, C.A.; van Schaik, R.H. OPRM1 and COMT Polymorphisms: Implications on Postoperative Acute, Chronic and Experimental Pain after Cardiac Surgery. Pharmacogenomics 2020, 21, 181–193. [Google Scholar] [CrossRef]
  51. Diatchenko, L.; Nackley, A.G.; Slade, G.D.; Bhalang, K.; Belfer, I.; Max, M.B.; Goldman, D.; Maixner, W. Catechol-O-Methyltransferase Gene Polymorphisms Are Associated with Multiple Pain-Evoking Stimuli. Pain 2006, 125, 216–224. [Google Scholar] [CrossRef]
  52. Phan, L.; Jin, Y.; Zhang, H.; Qiang, W.; Shekhtman, E.; Shao, D.; Revoe, D.; Villamarin, R.; Ivanchenko, E.; Kimura, M.; et al. Kattman ALFA: Allele Frequency Aggregator. 2020. Available online: www.ncbi.nlm.nih.gov/snp/docs/gsr/alfa/ (accessed on 2 April 2025).
  53. Hajj, A.; Peoc’h, K.; Laplanche, J.-L.; Jabbour, H.; Naccache, N.; Zeid, H.; Yazbeck, P.; Khabbaz, L. Genotyping Test with Clinical Factors: Better Management of Acute Postoperative Pain? Int. J. Mol. Sci. 2015, 16, 6298–6311. [Google Scholar] [CrossRef] [PubMed]
  54. Wu, B.; Hand, W.; Alexov, E. Opioid Addiction and Opioid Receptor Dimerization: Structural Modeling of the OPRD1 and OPRM1 Heterodimer and Its Signaling Pathways. Int. J. Mol. Sci. 2021, 22, 10290. [Google Scholar] [CrossRef] [PubMed]
  55. Hajj, A.; Obeid, S.; Sahyoun, S.; Haddad, C.; Azar, J.; Rabbaa Khabbaz, L.; Hallit, S. Clinical and Genetic Factors Associated with Resistance to Treatment in Patients with Schizophrenia: A Case-Control Study. Int. J. Mol. Sci. 2019, 20, 4753. [Google Scholar] [CrossRef]
  56. Boroń, A.; Suchanecka, A.; Chmielowiec, K.; Śmiarowska, M.; Chmielowiec, J.; Strońska-Pluta, A.; Recław, R.; Grzywacz, A. OPRM1 Gene Polymorphism in Women with Alcohol Use Disorder. Int. J. Mol. Sci. 2024, 25, 3067. [Google Scholar] [CrossRef]
  57. Mathur, S.; Patel, J.; Goldstein, S.; Hendrix, J.M.; Jain, A. Bispectral Index. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2024. [Google Scholar]
Ijms 26 03504 g001
Figure 1. Boxplot charts presenting significant relationships between polymorphisms and clinical parameters based on regression modelling (Table 3).
Figure 1. Boxplot charts presenting significant relationships between polymorphisms and clinical parameters based on regression modelling (Table 3).
Ijms 26 03504 g001
Table 1. Demographic characteristics of the study group.
Table 1. Demographic characteristics of the study group.
VariableMean ± SD/n (%)Range
Age, years13.33 ± 3.675.00–18.00
Sex, female32 (76.2)-
Weight, kg47.72 ± 16.3916.50 ± 82.00
SD—standard deviation.
Table 2. Descriptive statistics of analyzed clinical parameters by polymorphism groups.
Table 2. Descriptive statistics of analyzed clinical parameters by polymorphism groups.
PolymorphismnCRP 72 h Post-Surgery, Mean ± SDMean 24 h NRS Pain Rating, Mean ± SDSufentanil Mean Infusion Flow Rate (Weight-Adjusted), Mean ± SDPACU Length of Stay, Median (IQR)Coanalgesics, n (%)
rs1799971 OPRM1AA35134.74 ± 66.902.09 ± 1.260.09 ± 0.032.38 (1.89;2.74)17 (48.6)
AG799.97 ± 66.091.79 ± 1.190.08 ± 0.022.30 (2.03;2.37)6 (85.7)
rs1205 CRPCC17130.54 ± 64.631.91 ± 1.410.09 ± 0.042.52 (1.97;3.37)10 (58.8)
CT20121.22 ± 71.952.19 ± 1.190.09 ± 0.032.08 (1.85;2.42)10 (50.0)
TT5154.40 ± 62.811.85 ± 0.840.07 ± 0.032.43 (2.35;2.47)3 (60.0)
rs1045642 ABCB1AA10142.57 ± 72.252.42 ± 1.440.09 ± 0.032.18 (1.88;2.51)6 (60.0)
AG23129.80 ± 62.381.95 ± 1.270.09 ± 0.032.35 (1.89;2.76)10 (43.5)
GG9111.61 ± 77.681.83 ± 0.870.08 ± 0.022.38 (2.20;2.93)7 (77.8)
rs6269AA13132.59 ± 51.992.33 ± 1.040.09 ± 0.032.35 (1.98;2.50)8 (61.5)
AG29127.31 ± 73.861.91 ± 1.310.09 ± 0.032.30 (1.90;2.75)15 (51.7)
rs4633CC692.05 ± 68.881.46 ± 1.730.08 ± 0.022.56 (2.10;2.88)4 (66.7)
CT22140.20 ± 66.492.15 ± 1.180.09 ± 0.032.35 (2.00;2.69)13 (59.1)
TT14127.06 ± 66.732.11 ± 1.100.09 ± 0.032.15 (1.85;2.48)6 (42.9)
rs4818CC20120.00 ± 59.272.42 ± 0.970.09 ± 0.032.32 (2.05;2.50)14 (70.0)
CG22137.07 ± 74.211.68 ± 1.360.09 ± 0.032.37 (1.89;2.89)9 (40.9)
rs4680AA16120.48 ± 67.532.09 ± 1.150.08 ± 0.032.29 (1.95;2.52)8 (50.0)
AG20145.01 ± 67.322.12 ± 1.190.09 ± 0.032.35 (1.95;2.76)11 (55.0)
GG697.94 ± 61.441.58 ± 1.690.08 ± 0.022.19 (1.92;2.65)4 (66.7)
COMT haplotypeACCA/GTGG13160.77 ± 64.592.08 ± 1.260.09 ± 0.042.30 (1.88;2.52)5 (38.5)
ATCA/ATCA10119.55 ± 49.652.20 ± 1.090.09 ± 0.032.39 (2.00;2.51)5 (50.0)
Other19112.11 ± 72.171.92 ± 1.340.08 ± 0.022.30 (1.95;2.76)13 (68.4)
rs7832704 ENPP2AA5144.51 ± 44.082.40 ± 1.330.07 ± 0.032.38 (2.30;2.52)3 (60.0)
AG37126.84 ± 69.981.99 ± 1.230.09 ± 0.032.30 (1.88;2.73)20 (54.1)
rs1801253 ADRB1CC26134.91 ± 64.042.19 ± 1.350.09 ± 0.032.42 (2.02;2.77)13 (50.0)
CG14116.48 ± 78.041.95 ± 0.970.08 ± 0.022.02 (1.84;2.34)9 (64.3)
GG2138.62 ± 21.690.62 ± 0.530.06 ± 0.003.46 (3.10;3.82)1 (50.0)
SD—standard deviation; IQR—interquartile range.
Table 3. Outcomes of univariate regression models created to indicate the most important confounder for each clinical variable.
Table 3. Outcomes of univariate regression models created to indicate the most important confounder for each clinical variable.
Clinical ParameterAge, Years Gender, Female (vs. Male) Procedure Type, Expedium (vs. Nuvasive) Procedure Type, Other (vs. Nuvasive)
β/OR (95% CI)pβ/OR (95% CI)pβ/OR (95% CI)pβ/OR (95% CI)p
CRP 72 h post-surgery6.75 (1.30;12.20)0.01719.28 (−30.19;68.76)0.43521.18 (−38.03;80.38)0.474−1.25 (−53.06;50.55)0.961
Mean 24 h NRS pain rating0.06 (−0.04;0.17)0.2490.74 (−0.15;1.62)0.101−0.46 (−1.54;0.63)0.400−0.25 (−1.19;0.70)0.604
Sufentanil mean infusion flow rate (weight-adjusted)0.00 (0.00;0.00)0.0600.02 (0.00;0.04)0.084−0.02 (−0.04;0.01)0.2070.00 (−0.03;0.02)0.800
PACU length of stay0.01 (−0.06;0.08)0.718−0.39 (−0.98;0.21)0.1950.02 (−0.65;0.69)0.952−0.75 (−1.34;−0.17)0.013
Coanalgesics0.94 (0.79;1.12)0.5141.29 (0.30;5.50)0.7290.89 (0.16;5.33)0.8920.44 (0.09;1.95)0.288
β—model estimate from linear regression (all parameters except from coanalgesics); OR—odds ratio based on logistic regression (coanalgesics); CI—confidence interval. All outcomes were based on univariate regression models with clinical parameter as the dependent variable and a given confounder as the independent variable. The underlined confounders were chosen as the most important for each given clinical variable. No confounder was indicated for coanalgesics due to the condition of p < 0.250 not being met.
Table 4. Outcomes of multivariate regression models created to indicate the influence of polymorphism on clinical variables.
Table 4. Outcomes of multivariate regression models created to indicate the influence of polymorphism on clinical variables.
PolymorphismCRP 72 h Post-SurgeryMean 24 h NRS Pain RatingSufentanil Mean Infusion Flow Rate (Weight-Adjusted)PACU Length of StayCoanalgesics (Yes/No)
β (95% CI)pβ (95% CI)pβ (95% CI)pβ (95% CI)pOR (95% CI)p
rs1799971 OPRM1AAref ref ref ref ref
AG−32.12 (−84.85;20.61)0.225−0.26 (−1.28;0.76)0.612−0.01 (−0.03;0.01)0.410−0.28 (−0.95;0.39)0.4056.35 (0.95;126.67)0.102
rs1205 CRPCCref ref ref ref ref
CT−9.76 (−53.00;33.49)0.6500.25 (−0.57;1.08)0.5420.00 (−0.02;0.02)0.837−0.62 (−1.10;−0.14)0.0120.70 (0.18;2.57)0.592
TT0.67 (−69.15;70.49)0.9850.06 (−1.22;1.34)0.929−0.01 (−0.04;0.03)0.6600.03 (−0.71;0.77)0.9271.05 (0.14;9.61)0.962
rs1045642 ABCB1AAref ref ref ref ref
AG−12.66 (−62.23;36.91)0.608−0.37 (−1.33;0.58)0.433−0.01 (−0.03;0.01)0.4330.51 (−0.08;1.09)0.0870.51 (0.11;2.29)0.386
GG−17.05 (−78.41;44.31)0.577−0.44 (−1.60;0.72)0.451−0.02 (−0.05;0.01)0.1170.72 (0.01;1.43)0.0462.33 (0.33;21.56)0.410
rs6269AAref ref ref ref ref
AG9.41 (−35.39;54.20)0.673−0.27 (−1.12;0.58)0.529−0.01 (−0.03;0.01)0.5270.05 (−0.50;0.61)0.8430.67 (0.17;2.50)0.556
rs4633CCref ref ref ref ref
CT48.04 (−9.93;106.01)0.1020.68 (−0.46;1.81)0.2340.01 (−0.02;0.03)0.6380.02 (−0.72;0.76)0.9630.72 (0.09;4.58)0.737
TT20.56 (−41.83;82.95)0.5090.45 (−0.77;1.68)0.4610.01 (−0.02;0.04)0.372−0.21 (−0.99;0.57)0.5900.38 (0.04;2.61)0.337
rs4818CCref ref ref ref ref
CG18.59 (−21.05;58.22)0.349−0.64 (−1.40;0.11)0.0910.00 (−0.02;0.02)0.9410.21 (−0.28;0.70)0.3950.30 (0.08;1.03)0.063
rs4680AAref ref ref ref ref
AG46.24 (4.03;88.45)0.0330.34 (−0.55;1.22)0.4470.00 (−0.02;0.02)0.830−0.03 (−0.59;0.53)0.9141.22 (0.33;4.65)0.765
GG−21.04 (−78.38;36.31)0.462−0.42 (−1.59;0.76)0.4790.00 (−0.03;0.03)0.9050.00 (−0.78;0.79)0.9912.00 (0.30;17.59)0.488
COMT haplotypeACCA/GTGGref ref ref ref ref
ATCA/ATCA−48.74 (−101.52;4.03)0.069−0.10 (−1.18;0.99)0.8570.00 (−0.03;0.02)0.7460.06 (−0.62;0.75)0.8561.60 (0.30;8.90)0.581
Other−38.30 (−83.97;7.37)0.098−0.29 (−1.20;0.62)0.523−0.02 (−0.04;0.00)0.1150.02 (−0.56;0.61)0.9323.47 (0.82;16.32)0.099
rs7832704 ENPP2AAref ref ref ref ref
AG−1.93 (−65.13;61.28)0.951−0.56 (−1.74;0.62)0.3420.02 (−0.01;0.05)0.234−0.26 (−1.01;0.49)0.4880.78 (0.09;5.27)0.802
rs1801253 ADRB1CCref ref ref ref ref
CG−20.26 (−63.27;22.75)0.346−0.53 (−1.34;0.29)0.199−0.01 (−0.03;0.01)0.521−0.15 (−0.69;0.39)0.5811.80 (0.48;7.26)0.389
GG12.78 (−82.64;108.20)0.788−1.92 (−3.66;−0.17)0.032−0.04 (−0.08;0.01)0.0930.86 (−0.30;2.02)0.1401.00 (0.04;27.14)>0.999
β—model estimate from linear regression (all clinical parameters except from coanalgesics) expressing the relationship between polymorphism and clinical parameter; OR—odds ratio based on logistic regression (coanalgesics) expressing the relationship between polymorphism and usage of coanalgesics; CI—confidence interval. All models assumed clinical parameter as a dependent variable and polymorphism as an independent variable, with additional confounders treated as independent variables. Age was a confounder for CRP 72 h post-surgery and sufentanil mean infusion flow rate (weight-adjusted), sex was a confounder for mean 24 h NRS pain rating, and type of procedure was a confounder for PACU length of stay. Models for coanalgesics do not include any confounders due to all potential confounders having p > 0.250 in the univariate analysis (Table 3).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Turczynowicz, A.; Równy, J.; Przontka, W.; Grzesik, M.; Jakubów, P.; Kowalczuk, O. Do Single-Nucleotide Polymorphisms Affect Pain Intensity and Sufentanil Analgesia After Pediatric Scoliosis Correction Surgery? Int. J. Mol. Sci. 2025, 26, 3504. https://doi.org/10.3390/ijms26083504

AMA Style

Turczynowicz A, Równy J, Przontka W, Grzesik M, Jakubów P, Kowalczuk O. Do Single-Nucleotide Polymorphisms Affect Pain Intensity and Sufentanil Analgesia After Pediatric Scoliosis Correction Surgery? International Journal of Molecular Sciences. 2025; 26(8):3504. https://doi.org/10.3390/ijms26083504

Chicago/Turabian Style

Turczynowicz, Aleksander, Jakub Równy, Weronika Przontka, Magdalena Grzesik, Piotr Jakubów, and Oksana Kowalczuk. 2025. "Do Single-Nucleotide Polymorphisms Affect Pain Intensity and Sufentanil Analgesia After Pediatric Scoliosis Correction Surgery?" International Journal of Molecular Sciences 26, no. 8: 3504. https://doi.org/10.3390/ijms26083504

APA Style

Turczynowicz, A., Równy, J., Przontka, W., Grzesik, M., Jakubów, P., & Kowalczuk, O. (2025). Do Single-Nucleotide Polymorphisms Affect Pain Intensity and Sufentanil Analgesia After Pediatric Scoliosis Correction Surgery? International Journal of Molecular Sciences, 26(8), 3504. https://doi.org/10.3390/ijms26083504

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop